D'Elia Riccardo V, Harrison Kate, Oyston Petra C, Lukaszewski Roman A, Clark Graeme C
Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom.
Clin Vaccine Immunol. 2013 Mar;20(3):319-27. doi: 10.1128/CVI.00636-12. Epub 2013 Jan 2.
Inflammation is the body's first line of defense against infection or injury, responding to challenges by activating innate and adaptive responses. Microbes have evolved a diverse range of strategies to avoid triggering inflammatory responses. However, some pathogens, such as the influenza virus and the Gram-negative bacterium Francisella tularensis, do trigger life-threatening "cytokine storms" in the host which can result in significant pathology and ultimately death. For these diseases, it has been proposed that downregulating inflammatory immune responses may improve outcome. We review some of the current candidates for treatment of cytokine storms which may prove useful in the clinic in the future and compare them to more traditional therapeutic candidates that target the pathogen rather than the host response.
炎症是机体抵御感染或损伤的第一道防线,通过激活固有免疫和适应性免疫反应来应对各种挑战。微生物已经进化出多种策略来避免引发炎症反应。然而,一些病原体,如流感病毒和革兰氏阴性菌土拉弗朗西斯菌,确实会在宿主体内引发危及生命的“细胞因子风暴”,这可能导致严重的病理状况并最终导致死亡。对于这些疾病,有人提出下调炎症免疫反应可能会改善预后。我们综述了一些目前用于治疗细胞因子风暴的候选药物,这些药物未来可能在临床上发挥作用,并将它们与更传统的针对病原体而非宿主反应的治疗候选药物进行比较。